Safety of topical tobramycin powder during operative treatment of fractures
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf230 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Gregory M Schrank und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Tobramycin, Anti-Bacterial Agents, Surgical Wound Infection, Tibial Fractures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Department of Defense.
Abstract (Originalsprache)
Background
Despite its common practice, limited data exists on the pharmacokinetics and safety of topical tobramycin in fracture fixation surgery. This study aimed to evaluate the nephrotoxicity risk, systemic absorption, and clearance of topical tobramycin powder after application in tibial fracture wound beds.
Methods
This prospective, observational safety study was nested within a randomized controlled trial ‘Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of High-Risk Infection (TOBRA)’ (ClinicalTrials.gov ID #NCT04597008). Patients randomized to the treatment arm were administered topical vancomycin (1000 mg) and tobramycin (1200 mg) directly in the wound bed at the time of definitive fixation. The study included consecutive patients allocated to the treatment arm at a single trial site. The primary outcome was a change in renal function post-treatment, using the acute kidney injury network (AKIN) criteria.
Results
A total of 64 patients were enrolled. The median age of participants was 49 years and 39% were female. Using available data, 97% of patients did not experience acute kidney injury. Two patients were classified as AKIN stage 1 at 24 h after treatment; both patients’ serum creatinine returned to baseline levels at the 2-week measurement. Median peak tobramycin serum level was 2.5 mcg/mL (IQR 1.3, 4.3). All patients had a serum tobramycin level <2 mcg/mL at 24-h post-treatment.
Conclusions
A single dose of 1200 mg tobramycin powder administered locally during fracture fixation of the tibia does not lead to nephrotoxic serum levels or long-term changes to renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA.
- R Adams Cowley Shock Trauma Center, Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD, USA.
- Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Förderung
- Department of Defense
Zitieren
APA
Schrank, G. M., O'Hara, N. N., Lee, S., Degani, Y., Chung, S., Carlini, A. R., Castillo, R. C., & O'Toole, R. V. (2025). Safety of topical tobramycin powder during operative treatment of fractures. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf230
Vancouver
Schrank GM, O'Hara NN, Lee S, Degani Y, Chung S, Carlini AR, et al. Safety of topical tobramycin powder during operative treatment of fractures. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf230
BibTeX
@article{Schrank2025,
author = {Schrank, Gregory M and O'Hara, Nathan N and Lee, Sara and Degani, Yasmin and Chung, Suna and Carlini, Anthony R and Castillo, Renan C and O'Toole, Robert V},
title = {Safety of topical tobramycin powder during operative treatment of fractures},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf230}
}
EUVIMED